PROM1 and prostate cancer: A study by Armstrong and colleagues showed that more than 80% of CTC in patients with metastatic castration-resistant prostate cancer co-expressed epithelial proteins such as EpCAM and CK with mesenchymal proteins including N-cadherin and the stem cell marker CD133 [29].